Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

Insulin-like growth factors (IGF-I and IGF-II) are well known trophic factors and their specific receptors are uniquely distributed throughout the brain, being especially concentrated in the hippocampal formation. IGFs possess neurotrophic activities in the hippocampus, an area severely affected in Alzheimer disease. These data, together with the evidence that β-amyloid (Aβ)-derived peptides likely play an important role in the neurodegenerative process observed in Alzheimer disease, led us to investigate if IGFs could be neuroprotective to hippocampal neurons against toxicity induced by amyloidogenic derivatives. Exposure of rat primary hippocampal neurons to different concentrations of Aβ25–35, Aβ1–40, Aβ1–42, and human amylin produced marked toxicity, while similar concentrations of two control Aβ peptides—reverse (Aβ40–1) and scrambled sequence (Aβ25–35)—and rat amylin failed to exhibit any significant effect on neuronal survival. IGF-I (10–100 nM) significantly protected hippocampal neurons against neurotoxicity induced by Aβ derivatives and human amylin. The homolog IGF-II was also effective although less potent than IGF-I suggesting the involvement of a typical IGF-I receptor in the observed neuroprotective effect. Most interestingly, IGF-I (10–100 nM) was even able to rescue neurons pre-exposed (up to 4 days) to amyloidogenic peptides. Other neurotrophic factors are reported to lack such rescuing abilities. These results suggest that IGF-I may have unique properties as a potent neuroprotective and neurorescuing agent against amyloid-related neurotoxicity.

Bibliography

Doré, S., Kar, S., & Quirion, R. (1997). Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proceedings of the National Academy of Sciences, 94(9), 4772–4777.

Authors 3
  1. Sylvain Doré (first)
  2. Satyabrata Kar (additional)
  3. Rémi Quirion (additional)
References 59 Referenced 266
  1. 10.1073/pnas.90.22.10836
  2. 10.1016/0014-4886(95)90041-1
  3. 10.1097/00019052-199508000-00004
  4. 10.1111/j.1749-6632.1996.tb34441.x
  5. 10.1111/j.1749-6632.1996.tb34401.x
  6. 10.1111/j.1471-4159.1993.tb13658.x
  7. 10.1073/pnas.90.17.7951
  8. 10.1016/0006-8993(95)01032-7
  9. 10.1016/0166-2236(95)93892-2
  10. 10.1016/0306-4522(93)90455-O
  11. 10.1210/edrv-16-2-143
  12. Doré S. Kar S. & Quirion R. (1997) Neuroscience in press.
  13. S Kar, D Seto, U K Hanisch, R Quirion Soc Neurosci Abstr 20, 81 (1994). / Soc Neurosci Abstr by Kar S (1994)
  14. 10.1523/JNEUROSCI.12-04-01558.1992
  15. 10.1080/01616412.1994.11740207
  16. 10.1111/j.1460-9568.1996.tb01607.x
  17. 10.1111/j.1471-4159.1992.tb11330.x
  18. 10.1111/j.1471-4159.1993.tb07480.x
  19. 10.1016/0006-8993(91)91740-R
  20. 10.1046/j.1471-4159.1995.65010218.x
  21. 10.1016/0006-8993(94)91659-4
  22. 10.1016/0003-2697(86)90131-4
  23. 10.1002/jnr.490390416
  24. 10.1073/pnas.87.22.9020
  25. 10.1007/BF02189111
  26. 10.1042/bj3110001
  27. 10.1146/annurev.ne.17.030194.002421
  28. 10.1016/0006-291X(90)90400-H
  29. 10.1073/pnas.92.6.1989
  30. 10.1016/0167-4838(92)90411-6
  31. 10.1038/382685a0
  32. 10.1038/382716a0
  33. 10.1074/jbc.270.9.4205
  34. 10.1016/S0021-9258(18)98776-4
  35. 10.1074/jbc.270.31.18666
  36. 10.1074/jbc.271.14.8443
  37. 10.1073/pnas.91.22.10703
  38. 10.1016/0166-2236(93)90009-B
  39. 10.1073/pnas.92.20.9328
  40. 10.1016/0006-8993(96)00458-1
  41. 10.1038/372128a0
  42. 10.1016/0962-8924(96)81024-5
  43. 10.1016/0092-8674(94)90131-7
  44. 10.1016/0006-8993(94)90223-2
  45. 10.1097/00001756-199305000-00015
  46. 10.1046/j.1471-4159.1995.65010292.x
  47. C Sell, R Baserga, R Rubin Cancer Res 55, 303–306 (1995). / Cancer Res by Sell C (1995)
  48. G Rodriguez-Tarduchy, M K L Collins, I Garcia, A Lopez-Rivas J Immunol 149, 535–540 (1992). (10.4049/jimmunol.149.2.535) / J Immunol by Rodriguez-Tarduchy G (1992)
  49. 10.1002/j.1460-2075.1994.tb06630.x
  50. 10.1073/pnas.90.23.10989
  51. W D Le, W -J Xie, R G Smith, S H Appel Neurodegeneration 2, 227–236 (1995). / Neurodegeneration by Le W D (1995)
  52. 10.1126/science.275.5300.661
  53. 10.1016/0169-328X(94)00232-4
  54. M F Murphy, K Felice, M Gawel, D Gelinas, R Kratz, F Lai, D Lange, H Natter, S Rudnicki Am Neurol Assn Abstr 38, 335 (1995). / Am Neurol Assn Abstr by Murphy M F (1995)
  55. 10.1016/0031-9384(92)90159-Y
  56. 10.1016/0024-3205(94)00377-7
  57. 10.1016/0006-8993(95)01355-5
  58. 10.1097/00001756-199112000-00008
  59. S Doré, R Quirion, S Kar Soc Neurosci Abstr 21, 475 (1995). / Soc Neurosci Abstr by Doré S (1995)
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 10:31 a.m.)
Deposited 2 years, 4 months ago (April 22, 2023, 8:11 a.m.)
Indexed 4 weeks, 2 days ago (July 28, 2025, 5:34 p.m.)
Issued 28 years, 3 months ago (April 29, 1997)
Published 28 years, 3 months ago (April 29, 1997)
Published Online 28 years, 3 months ago (April 29, 1997)
Published Print 28 years, 3 months ago (April 29, 1997)
Funders 0

None

@article{Dor__1997, title={Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity}, volume={94}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.94.9.4772}, DOI={10.1073/pnas.94.9.4772}, number={9}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Doré, Sylvain and Kar, Satyabrata and Quirion, Rémi}, year={1997}, month=apr, pages={4772–4777} }